Neurogene (NGNE) Capital Expenditures (2013 - 2026)
Neurogene (NGNE) reported Capital Expenditures of $354000.0 for Q1 2026, down 54.62% on a YoY basis from $780000.0 in Q1 2025, and up 136.16% quarter-over-quarter from -$979000.0 in Q4 2025.
Neurogene (NGNE) Capital Expenditures (2013 - 2026) Analysis & Trends
Neurogene has reported Capital Expenditures for 14 years, with the latest figure at $354000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 54.62% year-over-year to $354000.0; the trailing twelve-month figure through Mar 2026 stood at -$350000.0 (down 125.64% YoY), and the FY2025 full-year result was $76000.0, down 89.53% from the prior year.
- Capital Expenditures for Q1 2026 stood at $354000.0, up from -$979000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $2.2 million in Q4 2022, with the low at -$979000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $218058.8 across 5 years, with a median of $128000.0 in 2023.
- The largest YoY upside for Capital Expenditures was 453.19% in 2025 against a maximum downside of 4356.52% in 2025.
- Neurogene's Capital Expenditures stood at $2.2 million in 2022, then sank by 94.19% to $128000.0 in 2023, then sank by 82.03% to $23000.0 in 2024, then plunged by 4356.52% to -$979000.0 in 2025, then soared by 136.16% to $354000.0 in 2026.
- The last three Capital Expenditures figures came in at $354000.0 (Q1 2026), -$979000.0 (Q4 2025), and $127000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | 354,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 354,000.00 |
| Mar 31, 2026 | 354,000.00 |
| Dec 31, 2025 | -979,000.00 |
| Dec 31, 2025 | -979,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |